Endogenous endophthalmitis in patients with intravenous opioid use: demographics and associated comorbidities
- PMID: 33506370
- DOI: 10.1007/s10792-021-01709-0
Endogenous endophthalmitis in patients with intravenous opioid use: demographics and associated comorbidities
Abstract
Purpose: To identify risk factors for endogenous endophthalmitis (EE) in hospitalized adults, under 65 years of age, with a history of intravenous opioid use and non-ocular infection.
Methods: The National Inpatient Sample Database was used to identify cases of EE with a recent history of intravenous opioid use disorder with associated non-ocular infection. Systemic and ocular comorbidities were identified using codes from the International Classification of Diseases, Ninth Revision (ICD-9). Descriptive and regression analyses were performed to evaluate the risk factors for EE using IBM SPSS 23.
Results: Of the 605,859 inpatients, 21-65 years age, who had a history of recent opioid-IVDU and an associated IVDU-associated systemic infection, 363 (0.1%) had EE. Systemic comorbidities such as diabetes mellitus, mitral valve disease, aortic valve disease, history of cardiac valve transplantation, chronic kidney disease/renal failure, cirrhosis, active or previous radiation therapy, and history of solid organ transplantation were significantly more prevalent in patients with EE. A significantly increased risk of EE in intravenous opioid users was noted if they were of male gender (OR = 1.84), Asian/Pacific Islander ethnicity (OR = 4.41), had history of cirrhosis (OR = 2.33), active or history of radiation therapy (OR = 14.74), history of solid organ transplantation (OR = 5.91), candidemia (OR = 15.22), and infectious endocarditis (OR = 4.83). Conversely, concurrent alcohol use disorder (OR = 0.35) decreased the risk of EE.
Conclusion: Various demographic variables and systemic comorbidities increased the risk of developing EE in inpatients with a history of intravenous opioid use with associated non-ocular infection.
Keywords: Endogenous endophthalmitis; Endophthalmitis; Intraocular infection; Intravenous drug use; Sepsis.
Similar articles
-
Risk factors for endogenous endophthalmitis in infectious endocarditis patients.Eye (Lond). 2025 Jan;39(1):125-132. doi: 10.1038/s41433-024-03390-w. Epub 2024 Oct 14. Eye (Lond). 2025. PMID: 39402169 Free PMC article.
-
Risk Factors for Endogenous Endophthalmitis in Hospitalized Patients with Candida Fungemia.Ophthalmol Retina. 2021 Jul;5(7):687-695. doi: 10.1016/j.oret.2020.10.007. Epub 2020 Oct 16. Ophthalmol Retina. 2021. PMID: 33075547
-
Trends in Endogenous Endophthalmitis in Rural and Urban Settings in the United States.Ophthalmic Epidemiol. 2023 Jun;30(3):300-306. doi: 10.1080/09286586.2022.2094965. Epub 2022 Jul 17. Ophthalmic Epidemiol. 2023. PMID: 35848205
-
Endogenous Endophthalmitis Associated With COVID-19: A Systematic Review on Its Incidence, Risk Factors, Causative Organisms, and Prognosis.Cureus. 2024 Sep 30;16(9):e70523. doi: 10.7759/cureus.70523. eCollection 2024 Sep. Cureus. 2024. PMID: 39479080 Free PMC article. Review.
-
Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction.Ophthalmology. 2000 Aug;107(8):1483-91. doi: 10.1016/s0161-6420(00)00216-5. Ophthalmology. 2000. PMID: 10919895 Review.
Cited by
-
Endogenous Endophthalmitis-The Clinical Significance of the Primary Source of Infection.J Clin Med. 2022 Feb 23;11(5):1183. doi: 10.3390/jcm11051183. J Clin Med. 2022. PMID: 35268274 Free PMC article. Review.
-
Klebsiella Endogenous Endophthalmitis During the COVID-19 Pandemic.J Vitreoretin Dis. 2023 May 8;7(4):316-321. doi: 10.1177/24741264231170462. eCollection 2023 Jul-Aug. J Vitreoretin Dis. 2023. PMID: 37920850 Free PMC article.
-
[Bacterial endogenous endophthalmitis : Spectrum of pathogens and drug therapy].Ophthalmologie. 2024 Apr;121(4):264-271. doi: 10.1007/s00347-024-01995-w. Epub 2024 Mar 4. Ophthalmologie. 2024. PMID: 38438813 Review. German.
-
Risk factors for endogenous endophthalmitis in infectious endocarditis patients.Eye (Lond). 2025 Jan;39(1):125-132. doi: 10.1038/s41433-024-03390-w. Epub 2024 Oct 14. Eye (Lond). 2025. PMID: 39402169 Free PMC article.
References
-
- Sadiq MA, Hassan M, Agarwal A et al (2015) Endogenous endophthalmitis: diagnosis, management, and prognosis. J Ophthalmic Inflamm Infect 5(1):32. https://doi.org/10.1186/s12348-015-0063-y - DOI - PubMed - PMC
-
- Modjtahedi BS, Finn AP, Papakostas TD, Durand M, Husain D, Eliott D (2017) Intravenous drug use-associated endophthalmitis. Ophthalmol Retina 1(3):192–199 - DOI
-
- Centers for Disease Control and Prevention. Patients who Inject Drugs (PWID). Centers for disease control and prevention website. July 18, 2019. Accessed June 20, 2020. https://www.cdc.gov/pwid/index.html
-
- HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2011. Agency for Healthcare Research and Quality, Rockville, MD
-
- HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2012. Agency for Healthcare Research and Quality, Rockville, MD
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical